Eriko Miyawaki

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Clinical potential of antibody-drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors.

Clinical potential of antibody-drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors.

Journal: Investigational new drugs

Published: June 23, 2025

Patient characteristics related to screening failure in Phase I trials.

Patient characteristics related to screening failure in Phase I trials.

Journal: BMC cancer

Published: April 30, 2025

Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.

Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.

Journal: Scientific reports

Published: May 18, 2023

Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.

Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.

Journal: Investigational new drugs

Published: July 16, 2022

Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.

Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.

Journal: Thoracic cancer

Published: April 15, 2022

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy.

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy.

Journal: Advances in radiation oncology

Published: March 15, 2022

Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancer.

Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancer.

Journal: Cancer medicine

Published: January 25, 2022

Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.

Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.

Journal: Thoracic cancer

Published: January 05, 2022

Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer.

Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer.

Journal: Investigational new drugs

Published: November 08, 2021

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.

Journal: Investigational new drugs

Published: August 25, 2021

Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.

Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.

Journal: Investigational new drugs

Published: August 14, 2021

Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors.

Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors.

Journal: Japanese journal of clinical oncology

Published: July 30, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026